

PRINCIPLES OF TISSUE ENGINEERING

Third Edition

Edited by

Robert Lanza

**VP Research and Scientific Development, Advanced Cell Technology
Worcester, Massachusetts
Adjunct Professor, Institute of Regenerative Medicine
Wake Forest University School of Medicine
Winston-Salem, North Carolina**

Robert Langer

**Institute Professor
Massachusetts Institute of Technology
Cambridge, Massachusetts**

Joseph Vacanti

**John Homans Professor of Surgery
Director, Laboratory for Tissue Engineering and Organ Fabrication
Harvard Medical School and Massachusetts General Hospital
Boston, Massachusetts**



AMSTERDAM • BOSTON • HEIDELBERG • LONDON
NEW YORK • OXFORD • PARIS • SAN DIEGO
SAN FRANCISCO • SINGAPORE • SYDNEY • TOKYO

Academic Press is an imprint of Elsevier



CONTENTS

Contributors	xix	III. The Cytoplasm	56
Foreword	xxix	IV. Growth and Death	58
Preface	xxxix	V. Cytoskeleton	60
Preface to the Second Edition	xxxiii	VI. Cell Adhesion Molecules	61
Preface to the First Edition	xxxv	VII. Extracellular Matrix	62
		VIII. Culture Media	63
		IX. Cells in Tissues	64
		X. Further Reading	65
Introduction to Tissue Engineering	1		
1. The History and Scope of Tissue Engineering	3	6. Organization of Cells into Higher-Ordered Structures	67
<i>Joseph Vacanti and Charles A. Vacanti</i>		<i>Jon D. Ahlstrom and Carol A. Erickson</i>	
I. Introduction	3	I. Introduction	67
II. Scientific Challenges	4	II. Molecular Mechanisms of the EMT	68
III. Cells	4	III. The EMT Transcriptional Program	70
IV. Materials	5	IV. Molecular Control of the EMT	72
V. General Scientific Issues	5	V. Conclusion	76
VI. Social Challenges	6	VI. References	76
VII. References	6		
2. The Challenge of Imitating Nature	7	7. The Dynamics of Cell–ECM Interactions	81
<i>Robert M. Nerem</i>		<i>M. Petreaca and Manuela Martins-Green</i>	
I. Introduction	7	I. Introduction	81
II. Cell Technology	8	II. Cell–ECM Interactions	84
III. Construct Technology	10	III. Signal Transduction Events During Cell–ECM Interactions	90
IV. Integration into the Living System	11	IV. Relevance for Tissue Engineering	93
V. Concluding Discussion	12	V. References	95
VI. Acknowledgments	13		
VII. References	13		
3. Moving into the Clinic	15	8. Matrix Molecules and Their Ligands	101
<i>Alan J. Russell and Timothy Bertram</i>		<i>Bjorn Reino Olsen</i>	
I. Introduction	15	I. Introduction	101
II. History of Clinical Tissue Engineering	16	II. Collagens — Major Constituents of ECM	102
III. Strategies to Advance Toward the Clinic	20	III. Elastic Fibers and Microfibrils	107
IV. Bringing Technology Platforms to the Clinical Setting	26	IV. Other Multifunctional Proteins in ECM	107
V. Transition to Clinical Testing	28	V. Proteoglycans — Multifunctional Molecules in the Extracellular Matrix and on Cell Surfaces	111
VI. Establishing a Regulatory Pathway	30	VI. Conclusion	112
VII. Conclusions	30	VII. References	112
VIII. Acknowledgments	30		
IX. References	31		
4. Future Perspectives	33	9. Morphogenesis and Tissue Engineering	117
<i>Mark E. Furth and Anthony Atala</i>		<i>A. H. Reddi</i>	
I. Clinical Need	33	I. Introduction	117
II. Current State of the Field	33	II. Bone Morphogenetic Proteins (BMPs)	118
III. Current Challenges	34	III. Cartilage-Derived Morphogenetic Proteins (CDMPs)	121
IV. Future Directions	34	IV. Pleiotropy and Thresholds	121
V. Future Challenges	42	V. BMPs Bind to Extracellular Matrix	122
VI. References	42	VI. BMP Receptors	122
		VII. Responding Stem Cells	123
Part I. The Basis of Growth and Differentiation	51	VIII. Morphogens and Gene Therapy	123
		IX. Biomimetic Biomaterials	124
5. Molecular Biology of the Cell	53	X. Tissue Engineering of Bones and Joints	124
<i>Jonathan Slack</i>		XI. Future Challenges	125
I. Introduction	53	XII. Acknowledgments	126
II. The Cell Nucleus	54	XIII. References	126

10. Gene Expression, Cell Determination, and Differentiation <i>William Nikovits, Jr., and Frank E. Stockdale</i>	129	III. Growth Factors and Cytokines Active as Early Mediators of the Inflammatory Process	195
I. Introduction	129	IV. Inflammatory Response Mediators Activate Transcription of Quiescent Genes	196
II. Determination and Differentiation	129	V. Biologic Properties of SIG (Chemokine) Family Members	197
III. MyoD and the bHLH Family of Developmental Regulatory Factors	131	VI. Regulation of <i>JE</i> Gene Expression by Glucocorticoids	197
IV. MEFs — Coregulators of Development	132	VII. Growth Factors and Accelerated Healing	197
V. Pax in Development	132	VIII. Role of Basic Fibroblast Growth Factor and Angiogenesis	199
VI. Conclusions	132	IX. Pleiotrophin Remodels Tumor Microenvironment and Stimulates Angiogenesis	200
VII. References	133	X. Other Roles of Growth Factors and Cytokines	201
Part II. <i>In Vitro</i> Control of Tissue Development	135	XI. Conclusions	201
11. Engineering Functional Tissues <i>Lisa E. Freed and Farshid Guilak</i>	137	XII. References	201
I. Introduction	137	15. Mechanochemical Control of Cell Fate Switching <i>Donald E. Ingber</i>	207
II. Key Concepts	138	I. Introduction	207
III. <i>In Vitro</i> Studies Aimed at Clinical Translation	139	II. Extracellular Matrix Structure and Function	207
IV. Representative <i>In Vitro</i> Culture Environments	139	III. Pattern Formation Through ECM Remodeling	209
V. Convective Mixing, Flow, and Mass Transfer	142	IV. Mechanochemical Switching Between Cell Fates	210
VI. Culture Duration and Mechanical Conditioning	145	V. Summary	213
VII. Conclusions	149	VI. The Future	213
VIII. Acknowledgments	150	VII. Acknowledgments	214
IX. References	150	VIII. References	214
12. Principles of Tissue Culture and Bioreactor Design <i>R. I. Freshney, B. Obradovic, W. Grayson, C. Cannizzaro, and Gordana Vunjak-Novakovic</i>	155	Part III. <i>In Vivo</i> Synthesis of Tissues and Organs	217
I. Introduction	155	16. <i>In Vivo</i> Synthesis of Tissues and Organs <i>Brendan A. Harley and Ioannis V. Yannas</i>	219
II. Basic Principles of Cell and Tissue Culture	155	I. Introduction	219
III. Principles of Bioreactor Design	164	II. Mammalian Response to Injury	220
IV. Summary	180	III. Methods to Treat Loss of Organ Function	221
V. Acknowledgments	180	IV. Active Extracellular Matrix Analogs	223
VI. References	180	V. Basic Parameters for <i>In Vivo</i> Regeneration Studies: Reproducible, Nonregenerative Wounds	227
13. Regulation of Cell Behavior by Extracellular Proteins <i>Amy D. Bradshaw and E. Helene Sage</i>	185	VI. Examples of <i>In Vivo</i> Organ Regeneration	228
I. Introduction	185	VII. Conclusions	235
II. Thrombospondin-1	185	VIII. Acknowledgments	236
III. Thrombospondin-2	187	IX. References	236
IV. Tenascin-C	187	Part IV. Models for Tissue Engineering	239
V. Osteopontin	188	17. Models as Precursors for Prosthetic Devices <i>Eugene Bell</i>	241
VI. SPARC	189	I. Introduction	241
VII. Conclusions	190	II. Pigmentation of the Living-Skin Equivalent (LSE) <i>In Vitro</i>	244
VIII. References	191		
14. Growth Factors <i>Thomas F. Deuel and Yunchao Chang</i>	193		
I. Introduction	193		
II. Wound Healing	194		

III. The Living-Skin Equivalent as an Immunological Model	244	V. Conclusions	304
IV. The Living-Skin Equivalent as a Disease Model	244	VI. References	305
V. Wound-Healing Model	246	22. Polymer Scaffold Fabrication	309
VI. Vascular Models without Cells	247	<i>Matthew B. Murphy and Antonios G. Mikos</i>	
VII. Vascular Models with Cells Added	247	I. Introduction	309
VIII. Conclusions	248	II. Fiber Bonding	310
IX. References	249	III. Electrospinning	311
18. Quantitative Aspects	251	IV. Solvent Casting and Particulate Leaching	311
<i>Alan J. Grodzinsky, Roger D. Kamm, and Douglas A. Lauffenburger</i>		V. Melt Molding	312
I. Introduction	251	VI. Membrane Lamination	312
II. Molecular Interactions with Cells	251	VII. Extrusion	312
III. Molecular and Cell Transport Through Tissue	253	VIII. Freeze-Drying	313
IV. Cell and Tissue Mechanics	256	IX. Phase Separation	313
V. References	260	X. High-Internal-Phase Emulsion	313
		XI. Gas Foaming	313
		XII. Polymer/Ceramic Composite Fabrication	314
		XIII. Rapid Prototyping of Solid Free Forms	315
		XIV. Peptide Self-Assembly	316
		XV. <i>In Situ</i> Polymerization	316
		XVI. Conclusions	317
		XVII. Acknowledgments	317
		XVIII. References	320
Part V. Biomaterials in Tissue Engineering	263	23. Biodegradable Polymers	323
19. Micro-Scale Patterning of Cells and Their Environment	265	<i>James M. Pachence, Michael P. Bohrer, and Joachim Kohn</i>	
<i>Xingyu Jiang, Shuichi Takayama, Robert G. Chapman, Ravi S. Kane, and George M. Whitesides</i>		I. Introduction	323
I. Introduction	265	II. Biodegradable Polymer Selection Criteria	323
II. Soft Lithography	266	III. Biologically Derived Bioresorbables	324
III. Self-Assembled Monolayers (SAMs)	266	IV. Synthetic Polymers	327
IV. Microcontact Printing and Microfeatures Used in Cell Biology	267	V. Creating Materials for Tissue-Engineered Products	332
V. Microfluidic Patterning	272	VI. Conclusion	333
VI. Laminar Flow Patterning	272	VII. References	333
VII. Conclusion and Future Prospects	274	24. Micro- and Nanofabricated Scaffolds	341
VIII. Acknowledgments	275	<i>Christopher J. Bettinger, Jeffrey T. Borenstein, and Robert Langer</i>	
IX. References	275	I. Introduction	341
20. Cell Interactions with Polymers	279	II. Adaptation of Traditional Micro-Scale Techniques for Scaffold Fabrication	342
<i>W. Mark Saltzman and Themis R. Kyriakides</i>		III. Three-Dimensional Scaffolds with Micro-Scale Architecture	346
I. Introduction	279	IV. Three-Dimensional Scaffold Assembly	348
II. Methods for Characterizing Cell Interactions with Polymers	279	V. Microfabrication of Cell-Seeded Scaffolds	352
III. Cell Interactions with Polymers	283	VI. Summary and Future Direction	356
IV. Cell Interactions with Polymers in Suspension	289	VII. References	357
V. Cell Interactions with Three-Dimensional Polymer Scaffolds and Gels	291	25. Three-Dimensional Scaffolds	359
VI. Cell Interactions Unique to the <i>In Vivo</i> Setting	292	<i>Ying Luo, George Engelmayr, Debra T. Auguste, Lino da Silva Ferreira, Jeffrey M. Karp, Rajiv Saigal, and Robert Langer</i>	
VII. References	292	I. Introduction	359
21. Matrix Effects	297	II. Three-Dimensional Scaffold Design and Engineering	360
<i>Jeffrey A. Hubbell</i>		III. Conclusions	370
I. Introduction	297	IV. References	371
II. Extracellular Matrix Proteins and Their Receptors	297		
III. Model Systems for Study of Matrix Interactions	301		
IV. Cell Pattern Formation by Substrate Patterning	304		

Part VI. Transplantation of Engineered Cells and Tissues	375	Part VII. Stem Cells	419
26. Tissue Engineering and Transplantation in the Fetus	377	30. Embryonic Stem Cells	421
<i>Dario O. Fauza</i>		<i>Alan Trounson</i>	
I. Introduction	377	I. Introduction	421
II. General Characteristics of Fetal Cells	378	II. Derivation of Human Embryonic Stem Cells (hESC)	422
III. Fetal Tissue Engineering	379	III. Selecting Embryos for Producing Embryonic Stem Cells	422
IV. Ethical Considerations	384	IV. Maintaining Embryonic Stem Cells	423
V. The Fetus as a Transplantation Host	384	V. Pluripotential Markers of Embryonic Stem Cells	423
VI. Conclusions	385	VI. Genetic Manipulation of Embryonic Stem Cells	424
VII. References	386	VII. Differentiation of Embryonic Stem Cells	424
27. Immunomodulation	389	VIII. Directing Differentiation of Embryonic Stem Cells	425
<i>Denise L. Faustman</i>		IX. Coculture Systems for Directed Differentiation of Embryonic Stem Cells	425
I. Introduction	389	X. Concluding Comments	426
II. Origin of the Designer Tissue Concept	390	XI. References	426
III. First Demonstration of the Concept	390	31. Adult Epithelial Tissue Stem Cells	431
IV. Expansion of Research on Designer Tissues	391	<i>Christopher S. Potten and James W. Wilson</i>	
V. Antibody Masking	391	I. Introduction	431
VI. Gene Ablation	392	II. A Definition of Stem Cells	432
VII. RNA Ablation	393	III. Hierarchically Organized Stem Cell Populations	433
VIII. Enzyme Ablation	393	IV. Skin Stem Cells	435
IX. Mechanisms of Graft Survival After Class I Donor Ablation or Antibody Masking	394	V. Intestinal Stem Cell System	437
X. Role of Class I Modifications in Resistance to Recurrent Autoimmunity	395	VI. Stem Cell Organization in Filiform Papillae on the Dorsal Surface of the Tongue	441
XI. Launching of Xenogeneic Human Clinical Trials in the United States Using Immunomodulation	396	VII. Generalized Scheme	441
XII. Comment	396	VIII. Adult Stem Cell Plasticity	442
XIII. References	397	IX. References	443
28. Immunoisolation	399	32. Embryonic Stem Cells as a Cell Source for Tissue Engineering	445
<i>Beth A. Zielinski and Michael J. Lysaght</i>		<i>Ali Khademhosseini, Jeffrey M. Karp, Sharon Gerecht, Lino Ferreira, Gordana Vunjak-Novakovic, and Robert Langer</i>	
I. Introduction	399	I. Introduction	445
II. Theory and Capsule Format	399	II. Maintenance of ESCs	446
III. Cell Sourcing	401	III. Directed Differentiation	448
IV. Host Immune Responses to Encapsulated Cells	401	IV. Isolation of Specific Progenitor Cells from ESCs	451
V. Conclusion	402	V. Transplantation	452
VI. References	403	VI. Future Prospects	454
29. Engineering Challenges in Immunobarrier Device Development	405	VII. Conclusions	454
<i>Amy S. Lewis and Clark K. Colton</i>		VIII. Acknowledgments	455
I. Introduction	405	IX. References	455
II. Engineering Challenges	406	33. Postnatal Stem Cells	459
III. Strategies for Improving Immunobarrier Devices	410	<i>Pamela Gehron Robey and Paolo Bianco</i>	
IV. Theoretical Analysis of PFC-containing Microcapsules	411	I. Introduction	459
V. Future Directions	416	II. Reservoirs of Postnatal Stem Cells	459
VI. References	416	III. Current Approaches to Tissue Engineering	460
		IV. Conclusions	465

V. Acknowledgments	466		
VI. References	466		
Part VIII. Gene Therapy	469		
34. Gene Therapy	471		
<i>Ronald G. Crystal and Stefan Worgall</i>			
I. Introduction	471		
II. Strategies of Gene Therapy	472		
III. <i>Ex Vivo</i> vs. <i>In Vivo</i> Gene Therapy	472		
IV. Chromosomal vs. Extrachromosomal Placement of the Transferred Gene	473		
V. Gene Transfer Vectors	474		
VI. Cell-Specific Targeting Strategies	480		
VII. Regulated Expression of the Transferred Gene	483		
VIII. Combining Gene Transfer with Stem Cell Strategies	485		
IX. Challenges to Gene Therapy for Tissue Engineering	487		
X. Acknowledgments	487		
XI. References	487		
35. Gene Delivery into Cells and Tissues	493		
<i>Ales Prokop and Jeffrey M. Davidson</i>			
I. Introduction	493		
II. Gene Delivery Systems	493		
III. Exploring the Role of Receptor Ligand Signaling and Receptor Clustering in Agent Delivery	495		
IV. Overview of Nanovehicle Uptake and Trafficking	497		
V. Stability of Nanovectors in Buffers and Biological Fluids: Steric vs. Electrostatic Stabilization	500		
VI. Localization and Targeting	501		
VII. Drug Loading	503		
VIII. Gene Delivery Systems (GDS)	504		
IX. Special Considerations for Gene Delivery Systems	507		
X. Outlook	509		
XI. Acknowledgment	510		
XII. References	510		
Part IX. Breast	517		
36. Breast Reconstruction	519		
<i>Lamont Cathey, Kuen Yong Lee, Walter D. Holder, David J. Mooney, and Craig R. Halberstadt</i>			
I. Introduction	519		
II. Cell Types for Soft-Tissue Engineering	521		
III. Materials	522		
IV. Animal Models	526		
V. Strategies to Enhance the Vascularization of Engineered Tissue	528		
VI. Special Considerations	530		
VII. Concluding Remarks	530		
VIII. References	531		
Part X. Cardiovascular System	535		
37. Progenitor Cells and Cardiac Homeostasis	537		
<i>Annarosa Leri, Toru Hosoda, Marcello Rota, Claudia Bearzi, Konrad Urbanek, Roberto Bolli, Jan Kajstura, and Piero Anversa</i>			
I. Introduction	537		
II. Organ Homeostasis	537		
III. Cardiac Homeostasis	539		
IV. Properties of Exogenous and Endogenous Cells for Cardiac Repair	541		
V. The Embryo as a Model of Progenitor Cell Engraftment and Plasticity	545		
VI. Conclusions	547		
VII. References	547		
38. Cardiac-Tissue Engineering	551		
<i>M. Radisic, H. Park, and G. Vunjak-Novakovic</i>			
I. Introduction	551		
II. Clinical Problem	551		
III. Problem Definition	552		
IV. Previous Work	554		
V. Biomimetic Approach to Cardiac-Tissue Engineering	554		
VI. Engineered Heart Tissue by Mechanical Stimulation of Cells in Collagen Gels	560		
VII. Cell-Sheet Tissue Engineering	563		
VIII. Summary and Current Research Needs	563		
IX. Acknowledgments	565		
X. References	566		
39. Blood Vessels	569		
<i>Luke Brewster, Eric M. Brey, and Howard P. Greisler</i>			
I. Introduction	569		
II. Current Status of Vascular Conduits	570		
III. Physical or Chemical Modification of Current Grafts to Improve Durability	572		
IV. Therapeutic Angiogenesis and Arteriogenesis	576		
V. Tissue-Engineered Vascular Grafts	577		
VI. Endovascular Stents and Stent Grafts	581		
VII. Conclusion	582		
VIII. References	582		
40. Heart Valves	585		
<i>Peter Marc Fong, Jason Park, and Christopher Kane Breuer</i>			
I. Introduction	585		
II. Heart Valve Function and Structure	585		
III. Cellular Biology of the Heart Valve	586		
IV. Heart Valve Dysfunction and Valvular Repair and Remodeling	588		
V. Application of Tissue Engineering Toward the Construction of a Replacement Heart Valve	590		
VI. Conclusion	597		
VII. References	597		

Part XI. Endocrinology and Metabolism	603		
41. Generation of Islets from Stem Cells	605		
<i>Bernat Soria, Abdelkrim Hmadcha, Francisco J. Bedoya, and Juan R. Tejedo</i>			
I. Introduction	605		
II. Islet Transplantation	606		
III. Alternative Sources of Islet Cells	608		
IV. Biomaterials	611		
V. Acknowledgments	615		
VI. References	616		
42. Bioartificial Pancreas	619		
<i>Athanassios Sambanis</i>			
I. Introduction	619		
II. Cell Types for Pancreatic Substitutes	620		
III. Construct Technology	623		
IV. <i>In Vivo</i> Implantation	626		
V. Concluding Remarks	629		
VI. Acknowledgments	630		
VII. References	630		
43. Engineering Pancreatic Beta-Cells	635		
<i>Hee-Sook Jun and Ji-Won Yoon</i>			
I. Introduction	635		
II. Engineering to Generate Insulin-Producing Cells	636		
III. Engineering to Improve Islet Survival	640		
IV. Vectors for Engineering Islets and Beta-Cells	641		
V. Conclusion	643		
VI. References	643		
44. Thymus and Parathyroid Organogenesis	647		
<i>Craig Scott Nowell, Ellen Richie, Nancy Ruth Manley, and Catherine Clare Blackburn</i>			
I. Introduction	647		
II. Structure and Morphology of the Thymus	647		
III. <i>In Vitro</i> T-Cell Differentiation	649		
IV. Thymus Organogenesis	650		
V. Summary	658		
VI. Acknowledgments	658		
VII. References	658		
Part XII. Gastrointestinal System	663		
45. Adult Stem Cells in Normal Gastrointestinal Function and Inflammatory Disease	665		
<i>Mairi Brittan and Nicholas A. Wright</i>			
I. Introduction	665		
II. Defining Properties of Adult Stem Cells	666		
III. Cells of the Intestine	666		
IV. Identification of Intestinal Stem Cells	669		
V. Pathways of Cellular Differentiation in the Intestine	670		
VI. Adult Stem Cell Plasticity	672		
VII. Bone Marrow Contribution to the Cells in the Adult Intestine	672		
VIII. Origin of the ISEMFs	673		
		IX. Bone Marrow-Derived Vascular Lineages Contribute to Tissue Regeneration in IBD	674
		X. Stem Cell Plasticity: <i>De Novo</i> Cell Generation or Heterokaryon Formation	675
		XI. Bone Marrow Transplantation as a Potential Therapy for Crohn's Disease	676
		XII. References	676
	46. Alimentary Tract		681
	<i>Shaun M. Kunisaki and Joseph Vacanti</i>		
	I. Introduction		681
	II. Tissue-Engineered Small Intestine		681
	III. Tissue-Engineered Esophagus		686
	IV. Tissue-Engineered Stomach		689
	V. Tissue-Engineered Large Intestine		691
	VI. Conclusions		692
	VII. References		692
	47. Liver Stem Cells		695
	<i>Eric Lagasse</i>		
	I. Introduction		695
	II. Definition of a Tissue-Derived Stem Cell		695
	III. Cellular Organization of the Adult Liver		696
	IV. Hepatocytes: The Functional Unit of the Liver with Stem Cell Properties		696
	V. Liver Stem Cells		699
	VI. Liver Stem Cells and Therapeutic Approaches		703
	VII. Conclusion		704
	VIII. References		704
	48. Liver		707
	<i>Gregory H. Underhill, Salman R. Khetani, Alice A. Chen, and Sangeeta N. Bhatia</i>		
	I. Introduction		707
	II. Liver Failure and Current Treatments		707
	III. Cell Sources for Liver Cell-Based Therapies		709
	IV. <i>In Vitro</i> Hepatic Culture Models		711
	V. Extracorporeal Bioartificial Liver Devices		717
	VI. Cell Transplantation		721
	VII. Three-Dimensional Hepatocellular Systems: Development of Implantable Therapeutic Constructs		722
	VIII. Animal Models		726
	IX. Conclusion		726
	X. References		726
Part XIII. Hematopoietic System	733		
49. Hematopoietic Stem Cells	735		
<i>Malcolm A. S. Moore</i>			
	I. Introduction		735
	II. Historical Background		735
	III. Properties of Hematopoietic Stem Cells (HSC)		736
	IV. Ontogeny of HSC		737
	V. Migration, Mobilization, and Homing of HSC		738

VI. HSC Proliferation and Expansion <i>In Vitro</i>	739	III. Tissue-Engineering Approach to Renal Function Replacement	802
VII. Negative Regulation of HSC	744	IV. References	809
VIII. Hematopoietic Stem Cell Niches	744	54. Genitourinary System	811
IX. Conclusion	745	<i>Anthony Atala</i>	
X. References	746	I. Introduction	811
50. Red Blood Cell Substitutes	749	II. Reconstitution Strategies	811
<i>Thomas Ming Swi Chang</i>		III. Role of Biomaterials	812
I. Introduction	749	IV. Vascularization	812
II. Modified Hemoglobin	750	V. Progress in Tissue Engineering of Urologic Structures	812
III. First-Generation Modified Hemoglobin	751	VI. Additional Applications	816
IV. New Generations of Modified Hemoglobin	753	VII. Conclusion	818
V. A Chemical Approach Based on Perfluorochemicals	755	VIII. References	818
VI. Conclusions	755	Part XV. Musculoskeletal System	821
VII. Link to Websites	756	55. Mesenchymal Stem Cells	823
VIII. Acknowledgments	756	<i>Faye H. Chen, Lin Song, Robert L. Mauck, Wan-Ju Li, and Rocky S. Tuan</i>	
IX. References	756	I. Introduction	823
51. Lymphoid Cells	759	II. MSC Biology Relevant to Musculoskeletal-Tissue Engineering	823
<i>Una Chen</i>		III. MSCs in Musculoskeletal Tissue Engineering	829
I. Introduction	759	IV. Conclusions and Future Perspectives	838
II. Properties of Lymphocytes	760	V. Acknowledgment	838
III. Lymphocyte Engineering: Reality and Potential	760	VI. References	838
IV. Inductive Model of Sequential Cell Commitment of Hematopoiesis	760	56. Bone Regeneration	845
V. Diagrams to Explain This Model	761	<i>Chantal E. Holy, F. Jerry Volenec, Jeffrey Geesin, and Scott P. Bruder</i>	
VI. Some Comments on This Model	761	I. Introduction	845
VII. Criteria for Engineering Developmental Stages of Lymphopoiesis	763	II. Cell-Based Approach to Bone-Tissue Engineering	846
VIII. Stages of Lymphopoiesis for Engineering	763	III. Growth Factor-Based Therapies	853
IX. Concluding Remarks and Prospects for Lymphocyte Engineering	779	IV. Conclusion and Future Trends	857
X. Acknowledgments	780	V. References	857
XI. References	780	57. Bone and Cartilage Reconstruction	861
Part XIV. Kidney and Genitourinary System	785	<i>Wei Liu, Wenjie Zhang, and Yilin Cao</i>	
52. Stem Cells in Kidney Development and Regeneration	787	I. Introduction	861
<i>Gregory R. Dressler</i>		II. Bone Reconstruction	861
I. Introduction	787	III. Clinical Application of Engineered Bone	867
II. Kidney Development	787	IV. Cartilage Reconstruction	868
III. Genes That Specify Early Kidney Cell Lineages	789	V. Conclusion	873
IV. Establishment of Additional Cell Lineages	792	VI. Acknowledgements	874
V. Regeneration and Renal Stem Cells	794	VII. References	874
VI. Acknowledgments	797	58. Regeneration and Replacement of the Intervertebral Disc	877
VII. References	797	<i>Lori A. Setton, Lawrence J. Bonassar, and Koichi Masuda</i>	
53. Renal Replacement Devices	801	I. Introduction	877
<i>H. David Humes</i>		II. IVD Structure and Function	878
I. Introduction	801	III. Biomaterials for Nucleus Pulposus Replacement	880
II. Basics of Kidney Function	801	IV. Cell-Biomaterial Constructs for IVD Regeneration	882
		V. Cellular Engineering for Intervertebral Disc Regeneration	886

VI. Growth Factors and Biologics for Intervertebral Disc Regeneration	889	Part XVI. Nervous System	945
VII. Gene Therapy for Intervertebral Disc Regeneration	889	63. Neural Stem Cells	947
VIII. Concluding Remarks	891	<i>Lorenz Studer</i>	
IX. Acknowledgments	891	I. Introduction	947
X. References	891	II. Neural Development	947
59. Articular Cartilage Injury	897	III. Neural Stem Cells	948
<i>J. A. Buckwalter, J. L. Marsh, T. Brown, A. Amendola, and J. A. Martin</i>		IV. Embryonic Stem Cell–Derived Neural Stem Cells and Neural Progeny	951
I. Introduction	897	V. Applications in Biology and Disease	955
II. Articular-Cartilage Injury and Joint Degeneration	898	VI. Conclusion	958
III. Mechanisms of Articular-Cartilage Injuries	898	VII. References	958
IV. Response of Articular Cartilage to Injury	900	64. Brain Implants	967
V. Preventing Joint Degeneration Following Injury	902	<i>Lars U. Wahlberg</i>	
VI. Promoting Articular Surface Repair	902	I. Introduction	967
VII. Conclusion	904	II. Cell Replacement Implants	968
VIII. References	904	III. Cell Protection and Regeneration Implants	970
60. Tendons and Ligaments	909	IV. Combined Replacement and Regeneration Implants	973
<i>Francine Goulet, Lucie Germain, A. Robin Poole, and François A. Auger</i>		V. Disease Targets for Brain Implants	974
I. Introduction	909	VI. Surgical Considerations	975
II. Need for Bioengineered Tendon and Ligament Substitutes	910	VII. Conclusions	975
III. Histological Description of Tendons and Ligaments	910	VIII. References	975
IV. Tissue-Engineered ACL Substitutes	911	65. Spinal Cord	977
V. Conclusion	915	<i>John W. McDonald and Daniel Becker</i>	
VI. Acknowledgments	916	I. Introduction	977
VII. References	916	II. The Problem	977
61. Mechanosensory Mechanisms in Bone	919	III. Spinal Cord Organization	978
<i>Upma Sharma, Antonios G. Mikos, and Stephen C. Cowin</i>		IV. Injury	978
I. Introduction	919	V. Spontaneous Regeneration	979
II. The Connected Cellular Network (CCN)	920	VI. Current Limitations and Approaches to Repair and Redefining Goals	979
III. Mechanosensation on the CCN	921	VII. Spinal Cord Development	980
IV. Mesenchymal Stem Cells	927	VIII. Embryonic Stem Cells	981
V. Acknowledgments	928	IX. Novel Approaches to CNS Repair	986
VI. References	928	X. Toward Human Trials	989
62. Skeletal-Tissue Engineering	935	XI. Conclusions	990
<i>Matthew D. Kwan, Derrick C. Wan, and Michael T. Longaker</i>		XII. Acknowledgments	991
I. Introduction	935	XIII. References	991
II. Distraction Osteogenesis	936	66. Protection and Repair of Audition	995
III. Critical-Sized Defects	937	<i>Richard A. Altschuler, Yehoash Raphael, David C. Martin, Jochen Schacht, David J. Anderson, and Josef M. Miller</i>	
IV. Cellular Therapy	937	I. Introduction	995
V. Cytokines	938	II. Interventions to Prevent Hearing Loss/Cochlear Damage	996
VI. Scaffolds	940	III. Hair Cell Regeneration	998
VII. Angiogenesis	940	IV. Auditory Nerve Survival Following Deafness	999
VIII. Tissue Engineering in Practice	941	V. Genetic Deafness	1000
IX. Conclusion	942	VI. Methods of Therapeutic Intervention	1000
X. References	942	VII. Conclusions	1002
		VIII. References	1003

Part XVII. Ophthalmic Applications	1009		
67. Stem Cells in the Eye	1011		
<i>Michael E. Boulton, Julie Albon, and Maria B. Grant</i>			
I. Introduction	1011		
II. Corneal Epithelial Stem Cells	1011		
III. Retinal Progenitor Cells	1017		
IV. Bone Marrow Stem Cells	1017		
V. Potential for Stem Cells in Ocular Repair and Tissue Engineering	1018		
VI. References	1018		
68. Corneal-Tissue Replacement	1025		
<i>Jeffrey W. Ruberti, James D. Zieske, and Vickery Trinkaus-Randall</i>			
I. Introduction	1025		
II. Synthetic Corneal Replacements	1029		
III. Corneal-Tissue Engineering	1031		
IV. Current State of Corneal-Tissue Engineering and Future Directions	1043		
V. References	1043		
69. Vision Enhancement Systems	1049		
<i>Gislin Dagnelie</i>			
I. Introduction	1049		
II. Visual System, Architecture, and (Dys)function	1049		
III. Current and Near-Term Approaches to Vision Restoration	1052		
IV. Emerging Application Areas for Engineered Cells and Tissues	1058		
V. Conclusion: Toward 20/20 Vision	1061		
VI. Acknowledgments	1061		
VII. References	1061		
Part XVIII. Oral/Dental Applications	1065		
70. Biological Tooth Replacement and Repair	1067		
<i>Anthony J. (Tony) Smith and Paul T. Sharpe</i>			
I. Introduction	1067		
II. Tooth Development	1067		
III. Whole-Tooth Tissue Engineering	1068		
IV. Dental-Tissue Regeneration	1071		
V. Conclusions	1075		
VI. References	1075		
71. Oral and Maxillofacial Surgery	1075		
<i>Simon Young, Kyriacos A. Athanasiou, Antonios G. Mikos, and Mark Eu-Kien Wong</i>			
I. Introduction	1079		
II. Special Challenges in Oral and Maxillofacial Reconstruction	1079		
III. Current Methods of Oral and Maxillofacial Reconstruction	1082		
IV. Relevant Strategies in Oral- and Maxillofacial-Tissue Engineering	1085		
V. Future of Oral- and Maxillofacial-Tissue Engineering	1091		
VI. References	1091		
72. Periodontal-Tissue Engineering	1095		
<i>Hai Zhang, Hanson K. Fong, William V. Giannobile, and Martha J. Somerman</i>			
I. Introduction	1095		
II. Factors for Periodontal Tissue Engineering and Regenerative Medicine	1097		
III. Current Approaches in Periodontal Tissue Engineering	1099		
IV. Future Directions	1104		
V. Acknowledgments	1105		
VI. References	1105		
Part XIX. Respiratory System	1111		
73. Progenitor Cells in the Respiratory System	1113		
<i>Valérie Besnard and Jeffrey A. Whitsett</i>			
I. Introduction: Lung Biology and Opportunities for Regeneration of the Lung	1113		
II. Complexity of Lung Structure Presents a Challenge for Tissue Engineering	1113		
III. Lung Morphogenesis	1114		
IV. Endogenous Progenitor Cells Play Critical Roles in Repair of the Respiratory Epithelium After Birth	1118		
V. Evidence for Nonpulmonary Stem Cells in the Lung	1120		
VI. Models for Study of Lung Regeneration <i>In Vitro</i>	1121		
VII. Summary and Conclusions	1121		
VIII. References	1122		
74. Lungs	1125		
<i>Anne E. Bishop and Julia M. Polak</i>			
I. Introduction	1125		
II. Lung Structure	1126		
III. Cell Sources for Lung Repair and Lung-Tissue Engineering	1126		
IV. Lung-Tissue Constructs	1129		
V. Conclusions	1130		
VI. References	1131		
Part XX. Skin	1135		
75. Cutaneous Stem Cells	1137		
<i>George Cotsarelis</i>			
I. Introduction	1137		
II. What Are Epithelial Stem Cells?	1138		
III. Localization of Epithelial Stem Cells	1138		
IV. <i>In Vitro</i> Assessment of Proliferative Potential	1140		
V. Multipotent Bulge Cells?	1142		
VI. Plasticity of Bulge Cells?	1143		
VII. Bulge Cells: The Ultimate Cutaneous Epithelial Stem Cells?	1143		
VIII. Role of Bulge Cells in Wound Healing	1143		
IX. Role of Bulge Cells in Tumorigenesis	1144		
X. Stem Cells and Alopecia	1144		
XI. Bulge Cells for Tissue Engineering	1144		

XII. Molecular Profile — Stem Cell Phenotype	1145	80. Tissue-Engineered Cartilage Products	1215
XIII. The Bulge as Stem Cell Niche	1145	<i>David W. Levine</i>	
XIV. Conclusion	1145	I. Introduction	1215
XV. Acknowledgments	1146	II. Clinical Experience with First-Generation ACI	1217
XVI. References	1146	III. Clinical Experience with Second-Generation ACI	1221
76. Wound Repair	1149	IV. Conclusions	1222
<i>Kaustabh Ghosh and Richard A. F. Clark</i>		V. References	1222
I. Introduction	1149	81. Tissue-Engineered Bone Products	1225
II. Basic Biology of Wound Repair	1150	<i>John F. Kay</i>	
III. Chronic Wounds	1157	I. Introduction	1225
IV. Tissue-Engineered Therapy: Established Practice	1157	II. Bone Healing	1226
V. Tissue-Engineered Therapy: New Approaches	1159	III. Osteogenic Grafting Materials	1226
VI. References	1161	IV. Osteoconductive Bone Graft Materials	1228
77. Bioengineered Skin Constructs	1167	V. Osteoinductive Bone Graft Materials	1229
<i>Vincent Falanga and Katie Faria</i>		VI. Composite Bone Grafting	1232
I. Introduction	1167	VII. Regulatory Issues	1232
II. Skin Structure and Function	1168	VIII. Examples of Tissue Engineering in Contemporary Clinical Orthopedics	1233
III. Engineering Skin Tissue	1172	IX. The Future	1233
IV. Epidermal Regeneration	1174	X. Conclusions	1235
V. Dermal Replacement	1174	XI. Acknowledgments	1235
VI. Composite Skin Grafts	1175	XII. References	1235
VII. Bioengineered Skin: FDA-Approved Indications	1176	82. Tissue-Engineered Cardiovascular Products	1237
VIII. Mechanisms of Action of Bioengineered Skin	1179	<i>Thomas Eschenhagen, Herrmann Reichenspurner, and Wolfram-Hubertus Zimmermann</i>	
IX. Conclusion	1182	I. Introduction	1237
X. References	1182	II. Clinical Need for Tissue-Engineered Cardiovascular Products?	1238
Part XXI. Clinical Experience	1187	III. Requirements for Clinical Application	1239
78. Current State of Clinical Application	1189	IV. Current Concepts and Achievements in Engineering Cardiovascular Products	1241
<i>Shaun M. Kunisaki and Dario O. Fauza</i>		V. State of Myocardial-Tissue Engineering	1243
I. Introduction	1189	VI. Bottlenecks	1246
II. Current Challenges	1189	VII. Summary	1247
III. Clinical Applications	1190	VIII. References	1248
IV. Conclusion	1198	83. Tissue-Engineered Organs	1253
V. References	1199	<i>Steve J. Hodges and Anthony Atala</i>	
79. Tissue-Engineered Skin Products	1201	I. Introduction	1253
<i>Jonathan Mansbridge</i>		II. Tissue Engineering: Strategies for Tissue Reconstitution	1253
I. Introduction	1201	III. Cell Sources	1254
II. Types of Therapeutic Tissue-Engineered Skin Products	1202	IV. Alternate Cell Sources	1254
III. Components of Tissue-Engineered Skin Grafts as Related to Function	1203	V. Therapeutic Cloning	1255
IV. Commercial Production of Tissue-Engineered Skin Products	1204	VI. Biomaterials	1256
V. Manufacture of Dermagraft and TransCyte	1206	VII. Growth Factors	1257
VI. Dermagraft and TransCyte Production Processes	1207	VIII. Vascularization	1257
VII. Clinical Trials	1209	IX. Clinical Applications	1257
VIII. Immunological Properties of Tissue-Engineered Skin	1210	X. Conclusion	1259
IX. Commercialization	1210	XI. References	1259
X. Future Developments	1211		
XI. Conclusion	1212		
XII. References	1212		

Part XXII. Regulation and Ethics	1263		
84. The Tissue-Engineering Industry	1265		
<i>Michael J. Lysaght, Elizabeth Deweerd, and Ana Jaklenec</i>			
I. Introduction	1265		
II. The Age of Innocence	1266		
III. The Perfect Storm	1267		
IV. The Present Era	1268		
V. Concluding Perspectives	1270		
VI. References	1270		
85. The Regulatory Path From Concept to Market	1271		
<i>Kiki B. Hellman</i>			
I. Introduction	1271		
II. Legislative Authority	1272		
III. Product Regulatory Process	1272		
IV. Product Premarket Submissions	1273		
V. Review of Product Premarket Submissions	1275		
VI. Human Cells, Tissues, and Cellular- and Tissue-Based Products	1275		
VII. Science and Product Development	1277		
VIII. Conclusion and Future Perspectives	1278		
IX. Acknowledgments	1279		
X. References	1279		
		86. Ethical Issues	1281
		<i>Laurie Zoloth</i>	
		I. Introduction	1281
		II. Are There Reasons, in Principle, Why Performing the Basic Research Should be Impermissible?	1282
		III. What Contextual Factors Should Be Taken into Account, and Do Any of These Prevent the Development and Use of the Technology?	1284
		IV. What Purposes, Techniques, or Applications Would Be Permissible and Under What Circumstances?	1285
		V. On What Procedures and Structures, Involving What Policies, Should Decisions on Appropriate Techniques and Uses Be Based?	1285
		VI. Conclusion	1286
		VII. References	1286
		Epilogue	1289
		Subject Index	1291